

**Brand Name:** Erivedge

**Generic:** vismodegib


**Type:** small molecule

**Year Accepted/Phase:** 2012

### **Mechanism:**

Vismodegib is a hedgehog pathway inhibitor, that works by targeting and inhibiting the Smoothened (SMO) receptor, a key component in the hedgehog signaling pathway, which is abnormally activated in most basal cell carcinomas.

### **Chemical Structure:**



### **Indication:**

Erivedge is indicated for the treatment of adults with metastatic BCC or locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation.

## **Clinical trials:**

### **ERIVANCE BCC Trial**

**Pubmed:** <https://pubmed.ncbi.nlm.nih.gov/22670903/>

**Purpose:** Evaluate the efficacy and safety of vismodegib in patients with advanced basal cell carcinoma, including those with locally advanced BCC (laBCC) and metastatic BCC (mBCC).

**Dates:** The ERIVANCE BCC trial was conducted between 2009 and 2011, with results published in 2012.

**Results:** The trial demonstrated that vismodegib had a significant clinical benefit, with a response rate of 43% in patients with locally advanced BCC and 30% in patients with metastatic BCC. The median duration of response was 7.6 months.

**Impact:** The positive results from the ERIVANCE BCC trial led to the approval of Erivedge for the treatment of advanced BCC.